Pharmaceutical companies’ pay-for-delay agreements, often found to be anticompetitive and recently targeted by the US Federal Trade Commission, pose major threats to industry mergers, a point highlighted by reports amid a pharma M&A boom.
While advocates are calling for a global consensus on such pay-for-delay deals, the matter has recently been complicated in the US when a court tossed a reverse payment lawsuit on the grounds that the payments were not made in “cash” and therefore not valid as anticompetitive under the Supreme Court’s decision in Actavis, which allowed regulators to prosecute over the deals.
But as uncertainty mounts over the agreements, pharmaceutical companies are similarly facing struggles as the deals complicate mergers and acquisitions.
Reports point to the 2011 announcement that Teva would acquire Cephalon in a $6.8 billion deal – an acquisition the company praised as one that would change the company’s future for the better, without revealing that Cephalon was believed to have participated in a pay-for-delay conspiracy.
The FTC has reportedly suggested a $6.8 billion settlement ordered upon Cephalon, a proposal made last January at a court hearing for the case. Reports say the lawsuit could be headed to a jury trial.
The FTC’s lawsuit against Cephalon highlights the risks of major pharmaceutical mergers and the uncertainty facing pay-for-delay cases even after the Supreme Court’s ruling.
Full content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI